Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) announced on Thursday that it has received a EUR2.4m grant from the German Federal Ministry of Education and Research (BMBF) to support its Phase 2 clinical trial for NOX-A12, a potential treatment for glioblastoma.
This non-dilutive funding, combined with other grants totalling approximately EUR5m, will support the randomised controlled study evaluating NOX-A12 in combination with bevacizumab.
The Phase 2 trial, approved by the US Food and Drug Administration (FDA) and the German regulator, aims to optimise the dosing regimen and assess the efficacy of the combination therapy.
MicuRx completes Phase III trial for MRX-4 for injection in China
Renalys Pharma secures Orphan Drug Designation in Japan for sparsentan
Minghui Pharmaceutical reports phase III success for MH004 ointment in atopic dermatitis
CBC Group acquires UCB's mature neurology and allergy business in China
MGI Tech collaborates with Universidad de San Martin de Porres
Allink Biotherapeutics completes USD42m Series A financing round
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children